ClinicalTrials.gg
DrugBiological

Patritumab deruxtecan clinical trials

Also written U3-1402 and MK-1022.

studies test it
25
open now
13
in phase 3
2
first study started
2016

How each study uses patritumab deruxtecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the patritumab deruxtecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Patritumab deruxtecan
20
HER3-DXd
17

Development codes

U3-1402
20
MK-1022
8

Studies by the year they started

25 studies that test it; most in 2024 (6)

Studies that test patritumab deruxtecan, by start year
YearStudies
20161
20171
20191
20202
20214
20222
20231
20246
20256
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
11
Phase 2
20
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 17 · Other 8

Merck Sharp & Dohme LLC (9) · Daiichi Sankyo (7) · SOLTI Breast Cancer Research Group (2) · Gustave Roussy, Cancer Campus, Grand Paris (2) · SCRI Development Innovations, LLC (1) · MedSIR (1) · Daiichi Sankyo Co., Ltd. (1) · Samsung Medical Center (1)

Often tested with

Tested in the same studies.

Sacituzumab tirumotecan (2) · Vibostolimab (1) · Boserolimab (1) · Anti-ILT4 Monoclonal Antibody MK-4830 (1) · Rolistobart (1) · Ifinatamab deruxtecan (1) · Ramucirumab (1) · Paclitaxel (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4

Studies that test patritumab deruxtecan.

Studies

Open first, then newest update. How each study uses patritumab deruxtecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 25

See all 25 studies that test patritumab deruxtecan →

Given beside what is tested · 1 — patritumab deruxtecan is usual care or a partner of the new treatment

Codes

What other systems call patritumab deruxtecan · ClinicalTrials.gg INT001428

  • MeSH (NLM) C000710748patritumab deruxtecanConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 3XPI7EG4W8PATRITUMAB DERUXTECANConfirmed FDA, NLM
  • NCI Thesaurus C136987Patritumab DeruxtecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.